JPM25: GSK's CSO shares science strategy behind deal-heavy year

21 hours ago · Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can …

$14
OFF

JPM25, Day 1: J&J Strikes $14.6B Deal For Intra-Cellular

2 weeks from now

2 days ago · JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave' ... such as GSK's proposed $1.15 billion deal for ... One of those is twice-a-year injection …

fiercepharma.com

$300
OFF

GSK Bets $300 Million On Genetics As CEO Plays Down Break-up Talk

2 weeks from now

Jul 25, 2018 · GSK is buying a $300 million (228.17 million pounds) stake in the Silicon Valley gene testing company 23andMe, giving it exclusive access to the Google-backed firm's vast …

reuters.com

80%
OFF

GSK Returns To Brain Drugs With Major Biotech Deal

2 weeks from now

Jul 2, 2021 · Alector's stock is also benefiting from the deal and the confidence GSK appears to have in the drug programs. The company's share price soared nearly 80% Friday morning, to …

biopharmadive.com

7%
OFF

(PDF) Gsk - A Case Study On The Strategy Of “Merger Of Equals” …

2 weeks from now

Jan 1, 2002 · GSK became the world’s largest producer of prescription drugs with market share of more than 7%. The merger also facilitated avoidance of increased R&D costs.

researchgate.net

FAQs about JPM25: GSK's CSO shares science strategy behind deal-heavy year Coupon?

What happened to GSK's oncology business?

The strategy has been years in the making. In 2015, GSK divested its oncology business, which Novartis acquired for $16 billion. Abdullah, who is GSK’s senior vice president, global head of oncology, research and development, said the drugmaker still retained its research infrastructure and early phase development capability in cancer. ...

How many new drugs will GSK & Flagship Pioneering develop?

Photographer: Vivian Wan/Bloomberg (Vivian Wan/Bloomberg) (Bloomberg) -- GSK Plc and Flagship Pioneering Inc. entered a partnership to develop as many as 10 new drugs in a deal that could pay more than US$7 billion to firms supported by the venture capital biotech. ...

Is GSK a good investment for Alector?

Hal Barron, GSK’s head of research and development, noted in a statement how his company’s work in immunology and human genetics should be an asset to Alector as it continues testing the two drugs, which are respectively called AL001 and AL101. The deal also comes at a notable time for neuroscience drug development. ...

Why did GSK buy Aiolos bio?

Earlier this year, GSK agreed to buy US biotech Aiolos Bio Inc. for as much as $1.4 billion to gain its experimental asthma drug. GSK shares rose as much as 1.3 per cent in London. They gained 7.7 per cent this year through Friday’s close. ...

What happened to GSK & Novartis?

In 2015, GSK divested its oncology business, which Novartis acquired for $16 billion. Abdullah, who is GSK’s senior vice president, global head of oncology, research and development, said the drugmaker still retained its research infrastructure and early phase development capability in cancer. In 2019, GSK decided to get back into the field. ...

What does the GSK deal mean for Alector?

For Alector, the GSK deal offers the backing of another large pharmaceutical partner. (Two of the company’s other experimental drugs are already licensed to AbbVie.) Additionally, it provides a cash infusion that could make it easier for the company to run more studies of its drugs. ...